Y-mAbs Therapeutics Inc · Q3 2023 earnings

Briefing

Y-mAbs reported a net product revenue of $20.0 million from DANYELZA and a net loss of $7.7 million for the third quarter of 2023.

Y-mAbs Therapeutics, Inc. reported a 59% increase in DANYELZA net product sales, reaching $20 million in Q3 2023 compared to the same period in 2022. The company's total revenues increased by 63% to $20.5 million. They also reported a net loss of $7.7 million, significantly lower than the $27.5 million loss in Q3 2022. With $86.6 million in cash and cash equivalents, Y-mAbs anticipates funding operations into 2027.

• DANYELZA net product revenues reached $20.0 million, a 59% increase compared to Q3 2022.
• Total revenues increased by 63% to $20.5 million, including $0.5 million in license revenue.
• Net loss decreased to $7.7 million, compared to a net loss of $27.5 million in Q3 2022.
• Cash and cash equivalents totaled $86.6 million, expected to support operations into 2027.

Headline financials

Revenue & EPS history

The company is updating and reiterating its full-year 2023 financial guidance.